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NEW STRATEGIES FOR TREATING PAIN IN PATIENTS WITH
OSTEOARTHRITIS
R.L. Leff
AstraZeneca, Wilmington, DE
Purpose:Over the years, a number of means to reduce the pain of
osteoarthritis have been shown to be useful, such as weight loss,
devices, intra-articular injections, and topical and oral medications.
Many are biomechanical in nature, while others are more physio-
logically based; often the result of building upon prior art by using
natural products, including (among many) aspirin, other NSAIDs,
topical capsaicin, intra-articular hyaluronic acids, cannabinoids,
and opioids. Nutritional supplements are often used, albeit with
less convincing evidence. The aim of most treatments is to reduce
pain, permitting greater mobility and ideally less of a need for more
risky or invasive interventions, such as arthroplasty. Some agents
for other diseases acting upon the central nervous system, includ-
ing the spinal cord, have been the source of exploratory studies
in osteoarthritis pain; central nervous system and other adverse
effects however often limit their usage. Agents more focused upon
the peripheral nervous system, such as the dorsal root ganglia,
may have fewer such issues. The challenge in osteoarthritis, with
heterogeneous sources of pain, is to ﬁnd effective interventions
and then also be able to choose those patients with the greatest
likelihood to beneﬁt, as there will usually be some risks involved,
especially with newly approved agents.
Methods: Emerging targets, including anti-NGF monoclonal an-
tibodies, ion channel antagonists (sodium and calcium), ther-
mosensitive ion channels (TRP/VR/vanilloid receptors), selective
cannabinoids, and others, will be discussed from available public
sources.
Results: The current pipeline of published compounds in devel-
opment for the treatment of pain, focusing upon that of possible
relevance to osteoarthritis will be presented.
Conclusions: Future treatment of osteoarthritis will be different
from that today. The search for better and/or additive agents
will continue; however, these will come at a price in known and
unknown safety concerns.
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UPDATE ON MATRIX DEGRADATION: ROLE OF MATRIX
DEGRADATION IN OA
C. Little
Univ. of Sydney, St Leonards, Australia
The key clinical feature of OA is disability associated with joint
pain and varying degrees of swelling, deformity, and decreased
range of motion. OA-disability is predominantly driven by pain,
although other factors such as reduced range of motion, weakness
and/or instability, and psychological phenomena undoubtedly play
a role in the disease burden. Progressive degradation and loss of
articular cartilage is a central although not pathognomonic feature
of OA, and the poor reparative capacity of this tissue means that
its loss may be irreparable. However, OA is a disease of the entire
“joint organ” with pathological change in intra-articular ligaments
and menisci, synovial ﬂuid, synovium, joint capsule and bone,
as well the cartilage. As OA involves pathology in all these joint
tissues, is speciﬁcally targeting cartilage matrix degradation a valid
approach to treating the clinical disease in patients? The answer
depends on which of the pathological tissues contributes most to
the disease pain and disability, and whether inhibiting pathological
change in one tissue, namely cartilage, modulates the others. Pain
in OA does not arise directly from damage to the aneural cartilage.
Sensory neurons are found in the synovium/joint capsule, intra-
articular ligaments and subchondral bone (SCB), with changes in
the latter strongly implicated in recent studies of pain and disease
progression in human knee OA.
Signiﬁcant advances in our understanding of the mechanisms of
cartilage matrix degradation in OA have been made in that past
decade by studying induced or age-related OA in genetically-
modiﬁed or transgenic mice. The effect on OA has been described
in the literature in mice with over 60 different genetic modiﬁcations.
Most of these (40) have reported increased spontaneous OA-like
cartilage damage in mutant mice compared with age-matched
wild-type (WT) animals. In the remaining studies, the response
to induced OA (usually surgical destabilization of the knee) has
been evaluated, with no or mixed effect reported in 10, increased
disease in 6, and signiﬁcant reduction of cartilage matrix damage
in 7 mice. This differential effect of various genetic modiﬁcations
in surgically-induced OA in mice, offers a great opportunity to
investigate the relationship between cartilage matrix degradation
and global joint pathological change. To date however, only 5 of
the published studies have reported on joint tissues other than
cartilage, 3 describing effects on osteophyte development, and in
only 2 the effect of the mutation on OA-induced changes in SCB.
Using histopathology scoring systems we have examined the rela-
tionship between the severity and progression of cartilage matrix
degradation and changes in SCB density, osteophyte maturity
and osteophyte size, over time in surgically-induced OA in 3
different WT mouse strains. The effect of different genetic mod-
iﬁcations that resulted in signiﬁcantly reduced cartilage erosion
(n = 2), worsened damage (n = 1), and no change (n = 1), on
the SCB and osteophytes in OA were examined. Meta-analysis
using partial correlations and general linear models, both within
strains and using pooled data were performed. Cartilage damage
increased signiﬁcantly with time after surgery in all WT strains.
While mean osteophyte size and maturity increased with time in
WT mice, there was no correlation with cartilage damage score.
SCB changes were dependent on background strain, with only
one showing a signiﬁcant change with time and OA progression.
Where cartilage damage was inhibited by the genetic mutation, a
signiﬁcant association was found between chondroprotection and
SCB change in only one of the strains. These studies suggest
independent regulation of bone and cartilage change in this OA
model, and that targeting cartilage matrix degradation will not in-
hibit SCB pathology or osteophyte development in post-traumatic
OA. How this impacts on OA-related pain and disability in these
mice is the subject of ongoing studies.
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DESIGNING AN OA CLINICAL TRIAL
J.-P. Pelletier, J.-P. Raynauld, J. Martel-Pelletier
Osteoarthritis Res. Unit, Notre-Dame Hosp., Univ. of Montreal
Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada
To date clinical studies in osteoarthritis (OA) have focused largely
on the alleviation of signs and symptoms. However, the main
objectives in the management of OA are not only to reduce
symptoms and minimize functional disability, but also to limit
progression of joint structural changes. The last decades have
witnessed several interesting advances in the treatment of OA.
A clearer understanding of the pathophysiology and risk factors
associated with the disease has facilitated the development of
new approaches to treatments aimed at speciﬁcally and effectively
retarding its progression. New classes of molecules that inhibit
one or more OA catabolic processes are under evaluation for their
potential to alter the degenerative process.
The design of OA drug trials aimed at evaluating the relief of
the disease symptoms has been well worked out over the last
few decades with ample expertise having been generated from
